HHS buying $290M worth of Amgen drug Nplate for radiation sickness in nuclear emergency
Nikolay Chekalin         

HHS is purchasing $290M worth of Amgen's (NASDAQ:AMGN) Nplate (romiplostim) for acute radiation sickness due to a radiological or nuclear emergency.
The treatment was developed by the company with assistance from the Biomedical Advanced Research and Development Authority and National Institute of Allergy and Infectious Diseases.
Nplate is approved for immune thromocytopenia, a blood disorder characterized by low platelet counts.